3T-403 / 3T Biosci - LARVOL DELTA

Breaking down solid tumor barriers with a bispecific T cell engager against a novel pHLA target [WITHDRAWN] (AACR 2025) - "3T-403, a CD3 bispecific T cell engager utilizing a T cell receptor mimic (TCRm) antibody has been developed to this novel target...Investigational new drug (IND) application completion is expected early 2026. Such a bispecific T cell engager against a novel target shows significant promise to address multiple solid tumor indications."

IO biomarker • Breast Cancer • Colorectal Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer